ClinicalTrials.gg
RecruitingNCT07651631REACHUpdated Aug 26, 2026

Rapid Evacuation and Access of Cerebral Hemorrhage Registry

An observational study in Intracerebral Hemorrhage, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Emory University · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Cerebral Hemorrhage with a site in United States — 31 open to participants now, 42 under way, 6 of them phase 3. Cerebral Hemorrhage · United States.

Planned enrollment
6th of 38
2,500 · median 245
Started
2026
with 9 others
Observational
38 of 109
14 open now
Primary completion
2033-06
later than 40 of 41 live
Registered
105th of 109
by date
Lead sponsor
3 of 109
Emory University

Among the 109 studies in Cerebral Hemorrhage with a site in United States, this one is the 6th largest by planned enrollment of the 38 observational ones that give a count, is one of 10 that started in 2026, is one of 38 observational ones, reaches primary completion later than 40 of the 41 other live ones, and was the 105th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

31 of the 109 studies in Cerebral Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Cerebral Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to quantify the real-world effect of minimally invasive surgery (MIS) in patients with acute spontaneous supratentorial intracerebral hemorrhage.

Read the detailed description

Intracerebral hemorrhage (ICH) is one of the most severe forms of stroke, accounting for nearly one-third of all strokes worldwide and affecting more than 3 million people annually. It remains associated with high mortality-over 40% of patients die within 30 days-and significant long-term disability among survivors. Basal ganglia hemorrhage is the most common location of spontaneous ICH and often results in profound neurological deficits, including weakness, sensory loss, visual impairment, and cognitive or speech difficulties. In the United States, more than 80,000 patients each year experience an acute ICH, and the condition contributes substantially to years of life lost, particularly among adults aged 35-65.

Despite decades of research, treatment options for ICH remain limited. Standard medical management focuses on blood pressure control, reversal of coagulopathy, prevention of hematoma expansion, and management of intracranial pressure. Traditional open craniotomy has not consistently improved functional outcomes and carries risks such as infection, rebleeding, and prolonged recovery. As a result, interest has grown in minimally invasive surgical (MIS) techniques designed to remove the hematoma while minimizing damage to surrounding brain tissue.

Over the past two decades, several MIS approaches have been developed, including catheter-based aspiration with thrombolytics, neuroendoscopic evacuation, minimally invasive puncture and drainage, and navigated trans-sulcal parafascicular surgery using tubular retractors. These techniques aim to reduce surgical trauma, improve hematoma evacuation, and limit secondary brain injury caused by inflammation, oxidative stress, and perihematomal edema.

Recent randomized trials have provided important insights into the potential benefits of MIS. The MISTIE III trial demonstrated procedural safety and suggested improved outcomes in patients who achieved substantial hematoma reduction. The ENRICH trial showed that early minimally invasive parafascicular surgery improved functional outcomes at 180 days for patients with lobar ICH and reduced mortality, ICU stay, and serious adverse events. Other trials, including MIND and SWITCH, have contributed additional data on safety, short-term disability, and the potential role of MIS in deep hemorrhages. Updated guidelines from the European Stroke Organization and the American Heart Association now support consideration of MIS for selected patients with supratentorial ICH.

Although evidence is growing, real-world practice varies widely due to differences in patient selection, surgical expertise, device availability, and institutional protocols. Randomized trials often include highly selected populations, limiting generalizability. There is a need for large-scale, prospective, real-world data to better understand how MIS is used across diverse clinical settings and to identify which patients benefit most.

The Rapid Evacuation and Access of Cerebral Hemorrhage (REACH) Registry is designed to address these gaps by prospectively collecting standardized data on patients undergoing MIS evacuation for spontaneous supratentorial ICH. The registry will capture patient demographics, comorbidities, hematoma characteristics, surgical techniques, timing of intervention, degree of hematoma evacuation, and clinical outcomes including mortality, complications, and functional status. By aggregating real-world data across multiple centers, the registry aims to evaluate the safety and effectiveness of different MIS approaches, identify predictors of favorable recovery, and support ongoing improvements in clinical practice.

Ultimately, the REACH Registry seeks to advance evidence-based care for patients with ICH, inform future clinical trials, and contribute to the refinement of national and international treatment guidelines

03

Conditions studied

  • Intracerebral Hemorrhage

Keywords

  • Intracerebral Hemorrhage
  • ICH is the basal ganglia
  • modified Rankin Scale
  • Arteriovenous Malformation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with acute, spontaneous supratentorial intracerebral hemorrhage.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Head CT demonstrating an acute, spontaneous, intracerebral hemorrhage
  • Hemorrhage volume ≥ 20 mLs
  • Minimally invasive surgical intervention performed within 7 days of hemorrhage

Exclusion criteria

Exclusion Criteria:

  • Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, recurrence of a recent ICH (\<1 year), as diagnosed with radiographic imaging
  • Infratentorial intraparenchymal hemorrhage, including midbrain, pontine, or cerebellum
  • Initial hospital arrival ≥ 24 hours after the onset of stroke symptoms
  • Last known normal is unknown
  • Historical Modified Rankin Score > 4
  • Known life-expectancy of less than 1 year prior to ICH
  • DNR or comfort measures only
  • Known pregnancy in female subjects
  • Inability or unwillingness of subject or legal guardian/representative to give written within 7 days of initial hospital arrival
  • Inability to meet follow up requiremen
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Minimally Invasive Surgical Groups

    * Surgical A: Endport evacuation (i.e., MIPS via BrainPath or similar device) * Surgical B: Endoscopic evacuation * Surgical C: Catheter-based evacuation * Surgical D: Other minimally invasive surgical techniques involving clot evacuation

  • Control Group

    No minimally invasive surgical hematoma evacuation performed; n=300 total, capped across 20 sites; may include patients undergoing decompressive hemicraniectomy or other standard medical/surgical approaches): * Basal Ganglia Controls (\>50% IVH or ICH volume ≥80 mL; n=100) * Lobar Controls (ICH volume ≥80 mL; n=100) * Primary Thalamic Controls (n=100) * ENRICH Trial Controls (ABG and lobar locations; n=150) * REACH Trial Controls (ABG location; n=maximum 300)

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS) at 180 Days

    Functional outcome will be assessed using the modified Rankin Scale (mRS), a 7-level ordinal scale ranging from 0 (no symptoms) to 6 (death). The primary endpoint evaluates real-world functional recovery following minimally invasive surgery (MIS) for acute supratentorial ICH. Structured interview performed in person or via telephone by trained study personnel; audio-recorded and centrally adjudicated.

    Time frame: Day 180 from baseline (±14 days)

  2. 30-Day Mortality

    All-cause mortality within 30 days of the initial hemorrhage.

    Time frame: Day 30 (±7 days)

Other outcomes

  1. modified Rankin Scale (mRS) at Additional Time Points

    The endpoint evaluates real-world functional recovery following minimally invasive surgery (MIS) for acute supratentorial ICH. Collected over phone or in-person via structured interview.

    Time frame: Day 7, 30, 90, 180, 365

  2. Post-Operative Infection or CSF Leak

    Incidence of surgical site infection or cerebrospinal fluid leak.

    Time frame: Baseline through Day 365

  3. Quality of Life (EQ-5D-5L)

    The EQ-5D-5L assesses health status across five dimensions: * Mobility * Self-care * Usual activities * Pain/discomfort * Anxiety/depression Each dimension has five levels (no problems, slight problems, moderate problems, severe problems, extreme problems), allowing patients to describe their health using a five-digit health state (e.g., 11223). Patients also complete a Visual Analogue Scale (VAS) rating their overall health from 0 (worst imaginable) to 100 (best imaginable)

    Time frame: Day 7, 30, 90, 180, 365

  4. Follow-Up Neuroimaging (24-Hour)

    Assessment of hematoma evacuation effectiveness and residual volume.

    Time frame: Within 24 hours post-procedure

  5. In-Hospital Mortality

    All-cause mortality occurring during the initial hospitalization.

    Time frame: From date of enrollment through the date of hospital discharge (upto 14 days)

  6. Change in Hematoma Volume

    Difference between initial hematoma volume and follow-up neuroimaging volume, assessed centrally by the Neuroimaging Core Lab.

    Time frame: Baseline to follow-up imaging (within first 10 days)

  7. Post-Operative Rebleeding With Neurologic Deterioration (Surgery Group Only)

    Rebleeding is defined as hematoma growth on follow-up imaging accompanied by neurologic decline (National Institute of Health Stroke Scale (NIHSS) increase ≥4 or Glasgow Coma Score (GCS) decrease ≤2)

    Time frame: Baseline through Day 10

  8. Time to Intervention

    Time from ictus (symptom onset) to MIS procedure.

    Time frame: From time of enrollment through the time of procedure (upto 100 days)

  9. Surgical Complications

    Any intraoperative or postoperative complication related to Minimally invasive surgery (MIS) technique, including device-related events.

    Time frame: Baseline through Day 365

  10. Residual Post-Operative Hemorrhage Volume

    Quantification of remaining hematoma volume after MIS.

    Time frame: Post-operative imaging (≤10 days)

  11. Serious Adverse Events (SAEs)

    SAEs include events resulting in death, life-threatening conditions, hospitalization, disability, or events requiring medical/surgical intervention.

    Time frame: Baseline through Day 365

  12. Hospital Length of Stay

    Total number of days from hospital admission to discharge.

    Time frame: From date of enrollment to the date of discharge (upto 4 weeks or more)

  13. Decompressive Hemicraniectomy

    Receipt of decompressive hemicraniectomy during the initial hospitalization.

    Time frame: Baseline through discharge (upto 100 days or more)

  14. ICU Length of Stay

    Number of days from ICU admission to ICU discharge.

    Time frame: From date of enrollment to the date of ICU discharge (upto 100 days or more)

  15. Duration of Mechanical Ventilation

    Total duration of mechanical ventilation during the initial hospitalization.

    Time frame: Time from enrollment to the time mechanical ventilation was stopped (upto 100 days or more)

07

Study locations

1 of 1 sites recruiting
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
    Recruiting
    • Alex Hall, DHSc, MS · Contact
    • Alex Hall, DHSc, MS · Principal investigator
    • Jonathan Ratcliff, MD, MPH · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared for special requests. REACH Trial must have the primary paper published, and the first 3 papers from the registry must be complete before the data becomes available for sharing.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Access criteria: Request to REACH Registry Executive Committee and/or REACH Registry Publications and Data Management Committee (PDMC)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2033, 82 months after the start.

Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 82 months is above that.

Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2026
First posted
Jun 16, 2026
StartActual
Aug 12, 2026
Primary completionEst.
Jun 2033
CompletionEst.
Jun 2033
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07651631
Lead sponsor
Emory University
Collaborators
The Marcus Foundation
Responsible party
Alex Hall (Assistant Professor, Emory University) — Principal investigator
First posted
Jun 16, 2026
Start date
Aug 12, 2026
Primary completion
Jun 2033 (estimated)
Completion
Jun 2033 (estimated)
Last update
Aug 26, 2026

Study contacts

Alex Hall, DHSc
Contact
alex.hall@emory.edu
404-778-1585
Alex Hall, DHSc
principal investigator · Emory University
Gustavo Pradilla, MD
principal investigator · Emory University
Jonathan Ratcliff,, MD, MPH
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion